Key facts
Detection method:Colorimetric,
Sample types:Nuclear Extracts,
Reacts with:Human,
Assay type:Semi-quantitative,
Sensitivity:< 1250 ng/well,
Assay time:3h 30m,
Assay Platform:Microplate reader
Product details:
AP1 (c-Fos/FosB/Fra1/c-Jun/JunB/JunD) Transcription Factor Assay Kit (Colorimetric) (ab207196) is a high throughput assay to quantify activation of AP1 family members (c-Fos/FosB/Fra1/c-Jun/JunB/JunD) at the same time in one assay. This assay combines a quick ELISA format with a sensitive and specific non-radioactive assay for transcription factor activation.
A specific double stranded DNA sequence containing the TPA-responsive element (TRE) (5' TGAGTCA 3) has been immobilized onto a 96-well plate. Activator protein-1 (AP1) dimers present in the nuclear extract specifically bind to the oligonucleotide. The primary antibodies used recognize epitopes on c-Fos, FosB, Fra-1, c-Jun, JunB or JunD proteins accessible only when the protein is activated and bound to its target DNA. An HRP-conjugated secondary antibody provides sensitive colorimetric readout at OD 450 nm. This product detects human, mouse and rat c-Fos, FosB and JunD, human and mouse c-Jun and human Jun B and Fra-1.
Key performance and benefits:
- Assay time: 3.5 hours (cell extracts preparation not included).
Detection limit: < 1.25 ug nuclear extract/well.
Detection range: 0.1 -20 ug nuclear extract/well.
Other Notes
The activator protein-1 (AP1) transcription factors belong to a large family of structurally related transcription factors that includes ATF1-4, c-Fos, c-Jun, c-Myc and C/EBP. The members of this family, named bZIP, share a dimerization domain with a leucine zipper motif and a DNA binding domain rich in basic residues (lysines and arginines). AP1 is composed of a mixture of heterodimeric complexes of proteins derived from the Fos and Jun families including c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB and JunD. Only Jun proteins can form transcriptionally active homodimers within AP1 members, or heterodimers with CREB/ATF members, to bind the CRE element (5'-TGACGTCA-3'). Primarily, AP1 dimers bind to DNA on a TPA-response element (TRE) with the 5'-TGA(C/G)TCA-3' sequence. Jun-Fos heterodimers form more stable complexes with TREs. These complexes display stronger transactivating activity than Jun-Jun homodimers.
Phosphorylation of AP1 family members by kinases is required for transactivation activity. In the case of c-Jun, the activation domain is regulated to a large extent by the JNK family of MAP kinases. JNK kinases phosphorylate c-Jun at Ser-63, resulting in the binding of c-Jun to the CBP/p300 family of transcriptional co-activators. For the Fos proteins, both N- and C-terminal domains flanking the bZIP domain require phosphorylation for biological activity.
AP1 expression is induced by multiple stimuli such as serum, growth factors, phorbol esters and oncogenes. These include peptide growth factors, cytokines of the TGF beta, TNF, and interferon families, neuronal depolarization and cellular stress. Upon serum starvation of human fibroblast cells, Fos and Jun protein production can be induced for up to 4 hours by adding serum. Interestingly, serum starvation lowers basal expression of FosB and c-Fos but has no significant effect on c-Jun.
AP1 proteins play a role in the expression of many genes involved in proliferation and cell cycle progression including neuronal apoptosis, learning process, drug-induced behavorial responses, bone growth and differentiation, and embryo development. For instance, cell transformation by oncogenes that function in the growth factor signal transduction pathway, such as
, results in a high increase in AP1 component protein expression. Therefore, AP1-regulated genes support the invasive process observed during malignancy and metastasis.
Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions-Multi, Appropriate long-term storage conditions-Multi, Storage information-Please refer to protocols
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein complex composed of JunB FRA1 c-Fos FosB c-Jun and JunD is collectively known as the AP-1 transcription factor. This complex regulates gene expression by binding to specific DNA sequences. AP-1 forms heterodimeric complexes typically with members of the Fos and Jun protein families including variants like FosB and JunD. These proteins have molecular masses ranging between 30 kDa and 60 kDa. AP-1 transcription factors are expressed in various tissues with higher expression levels in actively proliferating cells such as those in the skin and immune system.
Biological function summary
The AP-1 transcription factor complex influences cellular processes like proliferation differentiation and apoptosis. AP-1 acts as a critical regulator in cell cycle progression by promoting the expression of genes like cyclin D1. These transcription factors frequently interact with other complexes and cofactors to modulate gene expression profiles during cellular responses to environmental signals. They function as part of a larger transcriptional landscape involving interactions between other nuclear factors modifying gene expression.
Pathways
The AP-1 transcription factor plays key roles in the MAPK signaling pathway and the TGF-beta signaling pathway. Within these pathways it regulates gene expression for cell growth survival and immune responses. AP-1-associated proteins such as c-Jun and FRA1 interact through crosstalk with kinases like ERK and JNK influencing the expression of downstream target genes. The network interaction between these proteins and pathways highlights AP-1's significance in cellular signaling.
Altered AP-1 function links to cancer and inflammatory diseases. Overexpression or dysregulation of components like c-Fos and FosB associates with tumorigenesis in cancers such as breast and skin cancer. In inflammation AP-1 can lead to an enhanced immune response as seen in rheumatoid arthritis. Additionally aberrant regulation involving proteins like c-Jun in these conditions supports their role in pathogenesis and highlights them as potential therapeutic targets.
